Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction

Publisher： Karger

E-ISSN： 1662-6575|8|1|113-121

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.8, Iss.1, 2015-02, pp. : 113-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

Early Detection of Richter’s Transformation: Stable Disease with Dose-Reduced Gemcitabine and Local Radiation

By  

Oncology Research and Treatment, Vol. 29, Iss. 11, 2006-10 ,pp. : 526-528

Karger

Access to resources Recommend Favorite

Trastuzumab-Induced Myocardiotoxicity Mimicking Acute Coronary Syndrome

By  

Case Reports in Oncology, Vol. 5, Iss. 1, 2012-03 ,pp. : 125-133

Karger

Access to resources Recommend Favorite

The acute effects of a low and high dose of oral l-arginine supplementation in young active males at rest

By Forbes Scott C.   Bell Gordon J.  

Applied Physiology, Nutrition, and Metabolism, Vol. 36, Iss. 3, 2011-06 ,pp. : 405-411

NRC Research Press

Access to resources Recommend Favorite

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 139, Iss. 10, 2016-11 ,pp. : 2336-2342

John Wiley & Sons Inc

Access to resources Recommend Favorite